PT-141 (Bremelanotide): Dosage, Protocol, and Research Guide
FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder
Mechanism
Selective MC4R agonist that acts centrally in the hypothalamus to enhance sexual desire and arousal through dopaminergic pathways, unlike PDE5 inhibitors which work peripherally on blood flow.
Protocol at a glance
| Starting dose | 1mg |
|---|---|
| Maintenance dose | 1.75mg |
| Maximum dose | 1.75mg |
| Frequency | As needed, max 8 doses/month |
| Typical duration | On-demand therapy |
| Route | Subcutaneous |
| Injection site | Abdomen or thigh |
| Timing | 45 minutes before sexual activity |
Side effects
- Nausea
- Flushing
- Headache
- Injection site reactions
- Transient hypertension
Contraindications
- Uncontrolled hypertension
- Cardiovascular disease
Protocol notes
- FDA approved for premenopausal women with HSDD
- Effects last 6-12 hours
- Do not exceed 8 doses per month
- Works through CNS pathways, not vascular
- May increase blood pressure temporarily
Frequently asked questions
What is PT-141 (Bremelanotide) and how does it work?
PT-141, also known as Bremelanotide, is an FDA-approved selective melanocortin-4 receptor (MC4R) agonist that acts centrally in the hypothalamus to enhance sexual desire and arousal. Unlike PDE5 inhibitors (such as Viagra or Cialis) which work on blood vessels, PT-141 (Bremelanotide) operates through dopaminergic pathways in the central nervous system. This CNS mechanism makes it fundamentally different from vascular-focused approaches and allows it to address sexual desire at the neurological level rather than through peripheral blood flow enhancement.
What is the correct dosing protocol for PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) has a starting dose of 1mg and a maintenance dose of 1.75mg, which is also the maximum recommended dose. It is administered as an on-demand therapy via subcutaneous injection, with a maximum frequency of 8 doses per month. The peptide should be injected approximately 45 minutes before anticipated sexual activity. Effects typically last 6 to 12 hours, allowing for flexible use without daily dosing commitments.
Where do I inject PT-141 and what are common side effects?
PT-141 is administered via subcutaneous injection into the abdomen or thigh. Common side effects include nausea, flushing, headache, injection site reactions, and transient hypertension. The temporary elevation in blood pressure is typically brief and resolves naturally. Side effects are generally mild to moderate and often diminish with continued use. Individuals with uncontrolled hypertension or cardiovascular disease should not use PT-141 due to its potential to elevate blood pressure.
Is PT-141 legal and what does the research show?
PT-141 (Bremelanotide) is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its legal status is specific to regulatory approval and medical indication. The peptide has been studied in peer-reviewed clinical research. A randomized, placebo-controlled dose-finding trial (PMID 27181790) evaluated bremelanotide for female sexual dysfunctions in premenopausal women, and additional research (PMID 35076581) documented its use for female hypoactive sexual desire. These studies established the safety and efficacy profile used clinically today.
How does PT-141 differ from Viagra, Cialis, and other sexual performance medications?
PT-141 operates through a fundamentally different mechanism than PDE5 inhibitors like Viagra or Cialis. While those medications work peripherally to enhance blood flow to sexual organs, PT-141 acts centrally on the hypothalamus as a melanocortin receptor agonist, modulating dopaminergic pathways to enhance sexual desire itself. This makes PT-141 particularly suited for addressing hypoactive sexual desire disorder rather than erectile dysfunction, and it may be effective for individuals seeking a centrally-mediated approach or those who have not responded to vascular-focused therapies.
Can I use PT-141 more than 8 times per month?
No. PT-141 (Bremelanotide) should not exceed 8 doses per month. This frequency limit is part of the established dosing protocol and is important for maintaining safety and avoiding potential adverse effects from over-administration. As an on-demand therapy, PT-141 is designed for flexible use up to this maximum threshold, allowing users to match dosing frequency to their individual needs within these established guidelines.
Who should not use PT-141?
PT-141 is contraindicated for individuals with uncontrolled hypertension or significant cardiovascular disease. Because PT-141 can cause transient elevation in blood pressure, those with existing cardiovascular concerns or unmanaged hypertension face increased risk. A thorough cardiovascular assessment by a licensed physician is essential before beginning PT-141 use. Additionally, PT-141 is approved specifically for premenopausal women with HSDD, and use in other populations should be discussed with a healthcare provider.
How long do the effects of PT-141 last?
The effects of PT-141 (Bremelanotide) typically last 6 to 12 hours following subcutaneous injection. This duration allows for flexible timing of sexual activity, as the peptide should be injected approximately 45 minutes before anticipated activity. The on-demand nature of PT-141 use, combined with its sustained duration of effect, enables users to plan activity without committing to daily medication schedules.
More Athletic Performance peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.